Video Buzz v1

RelatedLinks

June 30th

• Local News | Malaria vaccine in the works | Seattle Times Newspaper

June 19th

• Reproductive Health Effects Found From Low Doses Of Bisphenol-A: Patisaul stresses that the research was done on rats, making it difficult to determine its applicability to humans, but notes that "this adds to a growing body of evidence that exposure to low doses of BPA during development can impact female reproductive health."

June 15th

• Division of Clinical Pharmacology | Indiana University Department of Medicine

June 3rd

• 21 CFR 58 Good Laboratory Practice Regulations (GLP)

May 24th

• CDER Drug and Biologic Approval Reports

May 19th

• Arkansas Researchers Unveil Breakthrough Cancer Treatment: The research, published in the Journal of Biomedical Optics, was announced at UALR by lead researchers Dr. Alex Biris, chief scientist with UALR's Nanotechnology Center, and Dr. Vladimir Zharov, director of the laser and nanomedicine labs of the Winthrop Rockefeller Cancer Institute at UAMS. Their method entails targeting cancer cells with nanoparticles, 25,000 times smaller than the diameter of a human hair, which attach themselves to the bad cells and reveal to doctors the precise location of the cancer. The nanoparticles attached to the cancerous cells are then heated by a laser and destroyed.

May 18th

• Nanobiotix Reports Exciting Preclinical Results Using Its nanoXray? Therapeutics Technology to Destroy Tumors | SYS-CON INDIA

April 27th

• Biophysical Methods in Pharmaceutical Lead Generation - SciTopics

March 4th

• MD Biosciences Expands Its Preclinical Contract Research Services by Offering Myocardial Infarct Models.
• MD Biosciences CRO Division Expands Its Preclinical Contract Research Services by Offering Myocardial Infarct Models: ST PAUL, Minn.--(BUSINE SS WIRE)--MD Biosciences, a Preclinical Contract Research Organization (CRO), announces today that it has expanded its preclinical contract research services by launching a line of in vivo models

February 25th

• Invitek, Inc. | Pre-Clinical Contract Research Services | San Francisco Bay Area | | In-Vivo | In-Vitro: INVITEK Inc. is a Pre-Clinical Development Company, located in the San Francisco Bay Area, Hayward, California. Offering a wide range of Pre-Clinical Contract Research Services In-Vivo and In-Vitro to pharmaceutical and biotechnology industries. The scientific team of Invitek consists of highly-qualifi ed and motivated individuals with more than 20 years of combined hands-on experience in innovative drug discovery and development. Specializing in design and implementation of new drugs and formulations for screening and testing efficacy in well-establish ed animal models of Diabetes, Obesity, Inflammation, Cancer, and Multiple Sclerosis; Pharmacokineti c; ADME; and Toxicology studies.

February 4th

• Dictionary of Cancer Terms - National Cancer Institute

January 22nd

• MPI Research

January 6th

• natural products research nutraceutical research Clinical Research Contract Research Organisation CRO herbal contract research Regulatory Affairs: natural products research nutraceutical research Clinical Research Contract Research Organisation CRO herbal contract research Regulatory Affairs

December 20th

• Humanized mouse model of Cooley's Anemia -- Huo et al. 0 (2008): M805681200v1 -- J. Biol. Chem.

RelatedImages

No Images Available!

Video Buzz > Preclinical

Video Buzz Video Player :)

No Matching Video

No video for Preclinical is available at this time.

Related Preclinical News

ABLYNX ANNOUNCES A NOVEL PRECLINICAL DEVELOPMENT CANDIDATE TARGETING ... - Market Wire

GHENT, Belgium, 29 June 2009 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, today announced that it has advanced ALX-0061, a new Nanobody®-based ...

Vical H1 Influenza Vaccine Delivers Robust Preclinical Results With ... - Phramalive.com

SAN DIEGO, June 30, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company's vaccine against A/H1N1 pandemic influenza (swine flu) produced robust immune responses well above the accepted protection threshold in ...

Alcon Commences Phase 2 Clinical Trial of NovaBay's NVC-422 for Viral ... - Earthtimes

NovaBay has a licensing and research collaboration agreement with Alcon, the world's leading eye care company, for use of its Aganocide(R) compounds in the eye, ear and sinus, and in contact lens solutions. Developed by NovaBay to mimic the body's ...

After Hours - XOMA - XOMA Presents the New Preclinical results with ... - Transworld News

WhisperfromWallStreet.com is a FREE award winning newsletter that specializes in sending alerts to our subscribers on stocks we think are going to run, why we think so, as well as teaching you how to become a better trader. We scan hundreds of stocks ...

Vical's Swine Flu Vaccine Shows Positive Response In Animal Study ... - RTT News

(RTTNews) - Biopharmaceutical company Vical Inc. (VICL: News ) Tuesday said that its vaccine against A/H1N1 pandemic influenza, or swine flu, produced robust immune responses in preclinical studies with 100% response. The company also said that it is ...

Preclinical Podcasts

Do you prefer to listen to your preclinical gossip? Check out Podzy Podcast Directory > Preclinical.

Preclinical Products

Looking for preclinical related products, then look no further. Try our new Preclinical Shop.